587 related articles for article (PubMed ID: 21429632)
1. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Shallal HM; Russu WA
Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
4. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
[TBL] [Abstract][Full Text] [Related]
5. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
[TBL] [Abstract][Full Text] [Related]
6. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
9. Development of new fluorescent xanthines as kinase inhibitors.
Kim D; Jun H; Lee H; Hong SS; Hong S
Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
11. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
12. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
13. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
Zhan W; Li Y; Huang W; Zhao Y; Yao Z; Yu S; Yuan S; Jiang F; Yao S; Li S
Bioorg Med Chem; 2012 Jul; 20(14):4323-9. PubMed ID: 22721924
[TBL] [Abstract][Full Text] [Related]
15. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
16. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
[TBL] [Abstract][Full Text] [Related]
17. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
19. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
20. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
